Renoprotective action of L-carnitine in fructose-induced metabolic syndrome

被引:23
|
作者
Rajasekar, P. [1 ]
Viswanathan, P. [2 ]
Anuradha, C. V. [1 ]
机构
[1] Annamalai Univ, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India
[2] Annamalai Univ, Rajah Muthiah Med Coll, Dept Pathol, Annamalainagar 608002, Tamil Nadu, India
来源
DIABETES OBESITY & METABOLISM | 2008年 / 10卷 / 02期
关键词
fructose diet; immunostaining; insulin resistance; lipotoxicity; oxidative stress; renal damage;
D O I
10.1111/j.1463-1326.2007.00825.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: Rats fed high dosage of fructose that form a well-known experimental model of the metabolic syndrome also display progressive renal disturbances. The present study evaluates the influence of L-carnitine (CA) administration on oxidant-antioxidant balance, protein damage and lipid levels in kidney of rats administered high dose of fructose. Methods: Adult male Wistar rats were divided into four groups of 10 rats each. Groups I and IV animals received starch-based control diet, while groups II and III rats were fed a high-fructose diet (60 g/100 g). Groups III and IV animals additionally received CA (300 mg/kg/day) for 60 days. The extent of lipid peroxidation, enzymatic and non-enzymatic antioxidants and lipid levels were measured after 60 days. The accumulation of nitrated and oxidatively modified proteins in kidney was also measured by immunohistochemical study with specific antibodies. Results: Fructose-fed rats exhibited increased levels of peroxidation end products, diminished antioxidant status, increased staining for the presence of 4-hydroxy-2-nonenal, 2,4-dinitrophenol and 3-nitrotyrosine protein adducts and lipid accumulation in kidney. CA administration attenuated these pathological renal alterations. Conclusions: The benefits of CA in this model suggest the therapeutic use of CA to counter the kidney changes associated with metabolic syndrome.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 50 条
  • [21] USE OF L-CARNITINE IN METABOLIC DISORDERS
    WINTER, SC
    ZORN, EM
    SZABO, S
    OHARA, T
    HIGASHI, L
    OPALA, GM
    KLETZKIN, M
    CLINICAL RESEARCH, 1989, 37 (01): : A185 - A185
  • [22] Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats
    Ibrahim, Mohamed A.
    Amin, Entesar F.
    Ibrahim, Salwa A.
    Abdelzaher, Walaa Y.
    Abdelrahman, Aly M.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 724 : 204 - 210
  • [23] POTENTIATION OF ACENOCOUMAROL ACTION BY L-CARNITINE
    MARTINEZ, E
    DOMINGO, P
    ROCACUSACHS, A
    JOURNAL OF INTERNAL MEDICINE, 1993, 233 (01) : 94 - 94
  • [24] Do Elevated Fructose Intake and Fructose-Induced Hyperuricemia Play a Role in the Genesis of Metabolic Syndrome?
    Grossklaus, R.
    Pfeuffer, M.
    Schrezenmeir, J.
    AKTUELLE ERNAHRUNGSMEDIZIN, 2007, 32 (06): : E1 - E12
  • [25] Research Progress on the Effects and Mechanisms of L-carnitine on Improving Metabolic Syndrome
    Sun C.
    Zhang Y.
    Chen Q.
    Li J.
    Li T.
    Wei Y.
    Gao X.
    Science and Technology of Food Industry, 2023, 44 (01) : 475 - 484
  • [26] EFFECT OF L-CARNITINE ON CARDIAC METABOLIC DAMAGES INDUCED BY DOXORUBICIN INVITRO
    NERI, B
    BARTALUCCI, S
    CIAPINI, A
    ANTICANCER RESEARCH, 1985, 5 (06) : 581 - 582
  • [27] Fructose-induced metabolic reprogramming of cancer cells
    Ting, Kenneth K. Y.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine
    Sayed-Ahmed, MM
    Shaarawy, S
    Shouman, SA
    Osman, AMM
    PHARMACOLOGICAL RESEARCH, 1999, 39 (04) : 289 - 295
  • [29] Effects of TNF-α antagonist infliximab on fructose-induced metabolic syndrome in rats
    Abdelhamid, Yasmine A.
    Elyamany, Mohammed F.
    Al-Shorbagy, Muhammad Y.
    Badary, Osama A.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2021, 40 (05) : 801 - 811
  • [30] Increased Inflammation in a Rhesus Monkey Model of Dietary Fructose-Induced Metabolic Syndrome
    Bremer, Andrew A.
    Stanhope, Kimber L.
    Graham, James L.
    Cummings, Bethany P.
    Havel, Peter J.
    DIABETES, 2011, 60 : A495 - A496